New Integrase Strand Transfer Inhibitor Approved To Treat HIV-1

• Autores: Diane S. Aschenbrenner
• Localización: American Journal of Nursing, ISSN 0002-936X, Vol. 113, Nº. 12, 2013, págs. 22-23
• Idioma: inglés
• DOI: 10.1097/01.naj.0000438862.37283.a8
• Texto completo no disponible (Saber más ...)
• Resumen

  • * A new drug, Dolutegravir (Tivicay), has been approved to treat HIV-1 infection in both treatment-naïve patients and those who have received prior therapy against HIV infection.

    * Possible serious adverse effects of the drug include hypersensitivity and abnormal liver function if the patient is coinfected with hepatitis B or hepatitis C.